Covidien releases successful drug-eluting balloon results; Dance Biopharm enters inhaled insulin joint venture;

> Covidien ($COV) released clinical data supporting its drug-coated balloon to treat lower limb blockages in peripheral artery disease patients. More

> Dance Biopharm entered into a joint venture with Harmony Asset to develop an inhaled insulin product in China and other Asian countries. Release

> Rexahn Pharmaceuticals ($RNN) in-licensed a novel oligonucleotide targeted drug delivery platform from Ohio State University, which has shown the ability to deliver compounds to cancer tumors in preclinical trials. Release

> Highly customizable coatings of foam-like polymers developed at the University of Rochester may be used for drug delivery, getting drugs into hard-to-reach places. Release

> Alliqua showed successful preclinical results for its investigational Lidocaine transdermal patch that compare favorably to current versions available on the market. Release

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.